Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder

References

• Polanczyk G , de Lima MS , Horta BL , Biederman J , Rohde LA . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942–8
   PubMed Web of Science ®Google Scholar
• Kessler RC , Adler L , Barkley R , Biederman J , Conners CK , Demler O , et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716–23
   PubMed Web of Science ®Google Scholar
• Fayyad J , De Graaf R , Kessler R , Alonso J , Angermeyer M , Demyttenaere K , et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402–9
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5th edition. Arlington: VA: American Psychiatric Publishing; 2013
   Google Scholar
• American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th edition. Arlington: VA: American Psychiatric Publishing; 2000
   Google Scholar
• Faraone SV , Biederman J , Spencer T , Wilens T , Seidman LJ , Mick E , Doyle AE . Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 2000;48:9–20
   PubMed Web of Science ®Google Scholar
• Sobanski E , Bruggemann D , Alm B , Kern S , Deschner M , Schubert T , et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2007;257:371–7
   PubMed Web of Science ®Google Scholar
• Sobanski E , Bruggemann D , Alm B , Kern S , Philipsen A , Schmalzried H , et al. Subtype differences in adults with attention-deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment. Eur Psychiatry 2008;23:142–9
   PubMed Web of Science ®Google Scholar
• Able SL , Johnston JA , Adler LA , Swindle RW . Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med 2007;37:97–107
   PubMed Web of Science ®Google Scholar
• Biederman J , Faraone SV . The effects of attention-deficit/hyperactivity disorder on employment and household income. Med Gen Med 2006;8:12
   PubMedGoogle Scholar
• De Graaf R , Kessler RC , Fayyad J , ten Have M , Alonso J , Angermeyer M , et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 2008;65:835–42
   PubMed Web of Science ®Google Scholar
• Küpper T , Haavik J , Drexler H , Ramos-Quiroga JA , Wermelskirchen D , Prutz C , Schauble B . The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescents. Int Arch Occup Environ Health 2012;85:837–47
   PubMed Web of Science ®Google Scholar
• Meier NM , Perrig W , Koenig T . Neurophysiological correlates of delinquent behaviour in adult subjects with ADHD. Int J Psychophysiol 2012;84:1–16
   PubMed Web of Science ®Google Scholar
• Edvinsson D , Bingefors K , Lindstrom E , Lewander T . ADHD-related symptoms among adults in out-patient psychiatry and female prison inmates as compared with the general population. Ups J Med Sci 2010;115:30–40
   PubMed Web of Science ®Google Scholar
• Young S , Moss D , Sedgwick O , Fridman M , Hodgkins P . A meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations. Psychol Med 2014;1–12
   Web of Science ®Google Scholar
• Ludolph AG , Kolch M , Plener PL , Schulze UM , Spröber N , Fegert JM . [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD]. Z Kinder Jugendpsychiatr Psychother 2009;37:405–11
   PubMed Web of Science ®Google Scholar
• Barkley RA , Fischer M , Smallish L , Fletcher K . Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45:192–202
   PubMed Web of Science ®Google Scholar
• Brod M , Pohlman B , Lasser R , Hodgkins P . Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study. Health Qual Life Outcomes 2012;10:47
   PubMed Web of Science ®Google Scholar
• Kooij SJ , Bejerot S , Blackwell A , Caci H , Casas-Brugué M , Carpentier PJ , et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010;10:67
   PubMed Web of Science ®Google Scholar
• Arnsten AF . Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry 2011;69:e89–99
   PubMed Web of Science ®Google Scholar
• Arnsten AF , Rubia K . Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry 2012;51:356–67
   PubMed Web of Science ®Google Scholar
• Bymaster FP , Katner JS , Nelson DL , Hemrick-Luecke SK , Threlkeld PG , Heiligenstein JH , et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699–711
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association . Highlights of Changes From DSM-IV-TR to DSM-5. Arlington: VA: American Psychiatric Publishing; 2013
   Google Scholar
• Durell TM , Adler LA , Williams DW , Deldar A , McGough JJ , Glaser PE , et al. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2013;33:45–54
   PubMed Web of Science ®Google Scholar
• Michelson D , Adler L , Spencer T , Reimherr FW , West SA , Allen AJ , et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112–20
   PubMed Web of Science ®Google Scholar
• Clemow DB . Suboptimal dosing of Strattera (atomoxetine) for ADHD patients. Postgrad Med 2014;126:196–8
   PubMed Web of Science ®Google Scholar
• Adler L , Dietrich A , Reimherr FW , Taylor LV , Sutton VK , Bakken R , et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry 2006;18:107–13
   PubMedGoogle Scholar
• Adler LA , Spencer T , Brown TE , Holdnack J , Saylor K , Schuh K , et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009;29:44–50
   PubMed Web of Science ®Google Scholar
• Goto T , Hirata Y , Takita Y , Trzepacz PT , Allen AJ , Song DH , et al. Efficacy and safety of atomoxetine hydrochloride in Asian adults with ADHD: A multinational 10-week randomized double-blind placebo-controlled Asian study. J Atten Disord 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Johnson M , Cederlund M , Rastam M , Areskoug B , Gillberg C . Open-label trial of atomoxetine hydrochloride in adults with ADHD. J Atten Disord 2010;13:539–45
   PubMed Web of Science ®Google Scholar
• Ni H-C , Lin YJ , Gau SS-F , Huang HC , Yang LK . An open-label, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD. J Atten Disord 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Sobanski E , Sabljic D , Alm B , Baehr C , Dittmann RW , Skopp G , Strohbeck-Kuehner P . A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 2012;45:100–7
   PubMed Web of Science ®Google Scholar
• Takahashi M , Takita Y , Goto T , Ichikawa H , Saito K , Matsumoto H , Tanaka Y . An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci 2011;65:55–63
   PubMed Web of Science ®Google Scholar
• Takahashi M , Goto T , Takita Y , Chung SK , Wang Y , Gau SS . Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder. Asia Pac Psychiatry 2014;6:62–70
   PubMed Web of Science ®Google Scholar
• Young JL , Sarkis E , Qiao M , Wietecha L . Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2011;34:51–60
   PubMed Web of Science ®Google Scholar
• Sutherland SM , Adler LA , Chen C , Smith MD , Feltner DE . An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry 2012;73:445–50
   PubMed Web of Science ®Google Scholar
• Guo Y , Fijal B , Marshall S , Li G , Ahl J , Nisenbaum L , et al. Comparison of efficacy and safety between intermediate and extensive/ultra-rapid metabolizers of atomoxetine in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled maintenance of response clinical trial. Poster presented at The Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 5 – 9 March 2013, Indianapolis, IN
   Google Scholar
• Adler LA , Spencer TJ , Williams DW , Moore RJ , Michelson D . Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008;12:248–53
   PubMed Web of Science ®Google Scholar
• Adler LA , Spencer TJ , Levine LR , Ramsey JL , Tamura R , Kelsey D , et al. Functional outcomes in the treatment of adults with ADHD. J Atten Disord 2008;11:720–7
   PubMed Web of Science ®Google Scholar
• Hirata Y , Goto T , Takita Y , Trzepacz PT , Allen AJ , Ichikawa H , Takahashi M . Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder. Asia Pac Psychiatry 2014;6:292–301
   PubMed Web of Science ®Google Scholar
• Marchant BK , Reimherr FW , Halls C , Williams ED , Strong RE , Kondo D , et al. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine. Atten Defic Hyperact Disord 2011;3:237–44
   PubMedGoogle Scholar
• Upadhyaya H , Ramos-Quiroga JA , Adler LA , Williams D , Tanaka Y , Lane JR , et al. Maintenance of response after open-label treatment with atomoxetine in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: A placebo-controlled, randomised withdrawal study. Eur J Psychiatry 2013;27:185–205
   Web of Science ®Google Scholar
• Block SL , Kelsey D , Coury D , Lewis D , Quintana H , Sutton V , et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila) 2009;48:723–33
   PubMed Web of Science ®Google Scholar
• Wernicke JF , Adler L , Spencer T , West SA , Allen AJ , Heiligenstein J , et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol 2004;24:30–5
   PubMed Web of Science ®Google Scholar
• Montoya A , Escobar R , Garcia-Polavieja MJ , Lachno DR , Alda JÁ , Artigas J , et al. Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine. J Child Neurol 2011;26:31–6
   PubMed Web of Science ®Google Scholar
• Leibowitz M , Ereshefsky L , Lin Q , Ledent E , Padich R , Allen AJ . Use of a biomarker of norepinephrine transporter (NET) inhibition to assess atomoxetine effects during clinically recommended dosing. Eur Neuropsychopharmacol 2005;15:S594–5
   Web of Science ®Google Scholar
• Morris DW , Toups M , Trivedi MH . Measurement-based care in the treatment of clinical depression. Focus 2012;10:428–33
   Google Scholar
• Heil SH , Holmes HW , Bickel WK , Higgins ST , Badger GJ , Laws HF , Faries DE . Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002;67:149–56
   PubMed Web of Science ®Google Scholar
• Jasinski DR , Faries DE , Moore RJ , Schuh LM , Allen AJ . Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008;95:140–6
   PubMed Web of Science ®Google Scholar
• Barkley RA , Fischer M , Smallish L , Fletcher K . The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002;111:279–89
   PubMed Web of Science ®Google Scholar
• McCarthy S . Pharmacological interventions for ADHD: how do adolescent and adult patient beliefs and attitudes impact treatment adherence? Patient Prefer Adherence 2014;8:1317–27
   PubMed Web of Science ®Google Scholar
• Bushe CJ , Savill NC . Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol 2014;28:204–11
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company . Strattera [US Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2014
   Google Scholar
• Michelson D , Faries D , Wernicke J , Kelsey D , Kendrick K , Sallee FR , et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83
   PubMed Web of Science ®Google Scholar
• Wietecha LA , Ruff DD , Allen AJ , Greenhill LL , Newcorn JH . Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. J Clin Psychiatry 2013;74:1217–23
   PubMed Web of Science ®Google Scholar
• Alatorre C , Kabul S , Montejano L , Kelsey D . Real world dosing patterns of atomoxetine in adults with attention-deficit/hyperactivity disorder. XVI Wold Congress of Psychiatry, Madrid, 2014
   Google Scholar
• del Campo N , Chamberlain SR , Sahakian BJ , Robbins TW . The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011;69:e145–57
   PubMed Web of Science ®Google Scholar
• Raiteri M , Del Carmine R , Bertollini A , Levi G . Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol 1977;41:133–43
   PubMed Web of Science ®Google Scholar
• Yamamoto BK , Novotney S . Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 1998;71:274–80
   PubMed Web of Science ®Google Scholar
• Clemow DB , Walker DJ . The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med 2014;126:64–81
   PubMed Web of Science ®Google Scholar
• Shire US . Vyvanse [US Package Insert]. Wayne, PA: Shire, Inc; 2012
   Google Scholar
• Arias-Carrión O , Stamelou M , Murillo-Rodriguez E , Menéndez-González M , Pöppel E . Dopaminergic reward system: a short integrative review. Int Arch Med 2010;3:24
   PubMedGoogle Scholar
• Levy F . Synaptic gating and ADHD: a biological theory of comorbidity of ADHD and anxiety. Neuropsychopharmacology 2004;29:1589–96
   PubMed Web of Science ®Google Scholar
• Leckman JF , Peterson BS , Pauls DL . Tic disorders. In Bloom FE , Kupfer DJ , editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 2000
   Google Scholar
• Adler LA , Liebowitz M , Kronenberger W , Qiao M , Rubin R , Hollandbeck M , et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009;26:212–21
   PubMed Web of Science ®Google Scholar
• Ravindran LN , Kim DS , Letamendi AM , Stein MB . A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 2009;29:561–4
   PubMed Web of Science ®Google Scholar
• Donnelly CL , Adler LA , Qiao M , Durell TM . Anxiety response to atomoxetine in patients with attention-deficit/hyperactivity disorder and comorbid anxiety. Poster presented at The 23rd Annual U.S.Psychiatric and Mental Health Congress (USPMHC), 18 – 21 November 2010, Orlando, FL
   Google Scholar
• Turner M , Wilding E , Cassidy E , Dommett EJ . Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res 2013;243:28–37
   PubMed Web of Science ®Google Scholar
• Gasior M , Bergman J , Kallman MJ , Paronis CA . Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology 2005;30:758–64
   PubMed Web of Science ®Google Scholar
• Wee S , Woolverton WL . Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend 2004;75:271–6
   PubMed Web of Science ®Google Scholar
• Upadhyaya HP , Desaiah D , Schuh KJ , Bymaster FP , Kallman MJ , Clarke DO , et al. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 2013;226:189–200
   PubMed Web of Science ®Google Scholar
• Darredeau C , Barrett SP , Jardin B , Pihl RO . Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol 2007;22:529–36
   PubMed Web of Science ®Google Scholar
• Teter CJ , McCabe SE , Boyd CJ , Guthrie SK . Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy 2003;23:609–17
   PubMed Web of Science ®Google Scholar
• Aldridge AP , Kroutil LA , Cowell AJ , Reeves DB , Van Brunt DL . Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder. Pharmacoeconomics 2011;29:621–35
   PubMed Web of Science ®Google Scholar
• [SAMHSA] Substance Abuse and Mental Health Services Administration . Treatment for Stimulant Use Disorders. Rockville: MD: Center for Substance Abuse Treatment, United States Department of Health and Human Services; 1999
   Google Scholar
• Carlson GA , Kelly KL . Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol 2003;13:137–42
   PubMed Web of Science ®Google Scholar
• Wilens TE , Adler LA , Weiss MD , Michelson D , Ramsey JL , Moore RJ , et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008;96:145–54
   PubMed Web of Science ®Google Scholar
• Wilens TE , Adler LA , Tanaka Y , Xiao F , D’Souza DN , Gutkin SW , Upadhyaya HP . Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Curr Med Res Opin 2011;27:2309–20
   PubMed Web of Science ®Google Scholar
• Adler LA , Guida F , Irons S , Shaw D . Open-label pilot study of atomoxetine in adults with ADHD and substance use disorder. J Dual Diagnosis 2010;6:196–207
   Web of Science ®Google Scholar
• Benegal V , Viswanath B , Narayanaswamy JC , Jose SP , Chakraborty V , Sankar D , et al. The efficacy of atomoxetine as adjunctive treatment for co-morbid substance use disorders and externalizing symptoms. Asian J Psychiatr 2013;6:544–7
   PubMedGoogle Scholar
• Adler LA , Sutton VK , Moore RJ , Dietrich AP , Reimherr FW , Sangal RB , et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 2006;26:648–52
   PubMed Web of Science ®Google Scholar
• Hirata Y , Goto T , Takita Y , Trzepacz PT , Allen AJ , Song DH , et al. Improvements of health-related QOL and executive functions of atomoxetine in Asian adults with ADHD: A multinational 10-week randomized,double-blind placebo-controlled Asian study. Int J Neuropsychopharmacol 2012;15:222
   Web of Science ®Google Scholar
• Adler LA , Clemow DB , Williams DW , Durell TM . Atomoxetine effects on executive function as measured by the BRIEF-A in young adults with ADHD: a randomized, double-blind, placebo-controlled study. PLoS ONE 2014;9:e104175
   PubMed Web of Science ®Google Scholar
• Adler L , Tanaka Y , Williams D , Trzepacz PT , Goto T , Allen AJ , et al. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. J Clin Psychopharmacol 2014;34:461–6
   PubMed Web of Science ®Google Scholar
• Brown TE , Holdnack J , Saylor K , Adler L , Spencer T , Williams DW , et al. Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord 2011;15:130–8
   PubMed Web of Science ®Google Scholar
• Ni HC , Shang CY , Gau SS , Lin YJ , Huang HC , Yang LK . A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 2013;16:1959–73
   PubMed Web of Science ®Google Scholar
• Barkley RA , Anderson DL , Kruesi M . A pilot study of the effects of atomoxetine on driving performance in adults with ADHD. J Atten Disord 2007;10:306–16
   PubMedGoogle Scholar
• Kay GG , Michaels MA , Pakull B . Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine. J Atten Disord 2009;12:316–29
   PubMed Web of Science ®Google Scholar
• Sobanski E , Sabljic D , Alm B , Dittmann RW , Wehmeier PM , Skopp G , Strohbeck-Kühner P . Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine. Eur Psychiatry 2013;28:379–85
   PubMed Web of Science ®Google Scholar
• Michelson D , Read HA , Ruff DD , Witcher J , Zhang S , McCracken J . CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007;46:242–51
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration . Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Rockville: MD: United States Food and Drug Administration; 2009
   Google Scholar
• Bangs ME , Jin L , Zhang S , Desaiah D , Allen AJ , Read HA , et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008;31:345–54
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication . Important safety label changes to cholesterol-lowering statin drug. 2014. Available from http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm
   Google Scholar
• Adler L , Wilens T , Zhang S , Durell T , Walker D , Schuh L , et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict 2009;18:393–401
   PubMed Web of Science ®Google Scholar
• Camporeale A , Porsdal V , De Bruyckere K , Tanaka Y , Upadhyaya H , Deix C , Deberdt W . Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials. J Psychopharmacol 2015;29:3–14
   PubMed Web of Science ®Google Scholar
• Habel LA , Cooper WO , Sox CM , Chan KA , Fireman BH , Arbogast PG , et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306:2673–83
   PubMed Web of Science ®Google Scholar
• Schelleman H , Bilker WB , Kimmel SE , Daniel GW , Newcomb C , Guevara JP , et al. Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. PLoS One 2013;8:e52991
   PubMed Web of Science ®Google Scholar
• Holick CN , Turnbull BR , Jones ME , Chaudhry S , Bangs ME , Seeger JD . Atomoxetine and cerebrovascular outcomes in adults. J Clin Psychopharmacol 2009;29:453–60
   PubMed Web of Science ®Google Scholar
• Spiller HA , Hays HL , Aleguas A Jr . Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 2013;27:531–43
   PubMed Web of Science ®Google Scholar
• Kashani J , Ruha AM . Isolated atomoxetine overdose resulting in seizure. J Emerg Med 2007;32:175–8
   PubMed Web of Science ®Google Scholar
• Bangs ME , Wietecha LA , Wang S , Buchanan AS , Kelsey DK . Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol 2014;24:426–34
   PubMed Web of Science ®Google Scholar
• Camporeale A , Day KA , Ruff D , Arsenault J , Williams D , Kelsey DK . Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. Drug Saf 2013;36:663–71
   PubMed Web of Science ®Google Scholar
• Biederman J , Wilens T , Mick E , Milberger S , Spencer TJ , Faraone SV . Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995;152:1652–8
   PubMed Web of Science ®Google Scholar